Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy

Young breast cancer women are often treated with adjuvant chemotherapy and neoadjuvant chemotherapy regiments include cyclophosphamide, anthracyclines and a taxane. These treatments can adversely affect ovarian function across the lifespan, causing premature menopause, infertility, and POI. AMH is currently the most robust marker of prediction of ovarian injury in cancer patients during chemotherapy in compare with other sexual hormone marker (such as follicle stimulating hormone (FSH), inhibin B) and ovarian volume, and is a more convenient way of prediction of ovarian reserve compare antral follicle count (AFC). But most of the patients' AMH levels become undetectable (using common AMH kits) after several cycle of chemotherapy, and some of these patients' AMH levels will maintained at a low level after chemotherapy, while others will recover. Using the ultrasensitive AMH detection method is expected to accurately assess the ovarian reserve during the chemotherapy treatment, predicting the risk of ovarian failure, and providing patients with ovarian and fertility function protection recommendations, such as using GnRHa regents during treatment and providing assisted reproductive technology consultants.

Inclusion criteria

• Female 18-50 years.
• Suffering from breast cancer.
• Treated with adjuvant or neoadjuvant chemotherapy.
• Having regular menstrual cycle before chemotherapy.

Exclusion criteria

• Bilateral oophorectomy or ovarian irradiation before enrollment.
• Prior chemotherapy.
• Oral contraceptives before enrollment.
• Pregnancy or lactation.